BRPI0313694B8 - derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção - Google Patents

derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção

Info

Publication number
BRPI0313694B8
BRPI0313694B8 BRPI0313694A BR0313694A BRPI0313694B8 BR PI0313694 B8 BRPI0313694 B8 BR PI0313694B8 BR PI0313694 A BRPI0313694 A BR PI0313694A BR 0313694 A BR0313694 A BR 0313694A BR PI0313694 B8 BRPI0313694 B8 BR PI0313694B8
Authority
BR
Brazil
Prior art keywords
optionally substituted
alkyl
medicinal
intermediates
composition containing
Prior art date
Application number
BRPI0313694A
Other languages
English (en)
Other versions
BRPI0313694B1 (pt
BR0313694A (pt
Inventor
Teranishi Hirotaka
Shimizu Kazuo
Tomae Masaki
Isaji Masayuki
Fushimi Nobuhiko
Yonekubo Shigeru
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR0313694A publication Critical patent/BR0313694A/pt
Publication of BRPI0313694B1 publication Critical patent/BRPI0313694B1/pt
Publication of BRPI0313694B8 publication Critical patent/BRPI0313694B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

"derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção". um derivado de pirazol representado pela fórmula geral: em que r^ 1^ é h, alquila c~ 1-6~ opcionalmente substituído etc.; qualquer um de q ou t é o grupo da fórmula ou da fórmula, enquanto o outro é alquila c~ 1-6~ opcionalmente substituído etc.; r^ 2^ é h, halogênio, oh, alquila c~ 1-6~ opcionalmente substituído etc.; x é a ligação simples, 0, ou s; y é alquileno c~ 1-6~ opcionalmente substituído etc.; z é -rh, -cor^ c^ etc. (r^ b^ é alquila c~ 1-6~ opcionalmente substituído, etc.; e r^ c^ é alquila c~ 1-6~ opcionalmente substituído etc.); r^ 4^ é h, alquila c~ 1-6~ opcionalmente substituído etc. ; e r^ 3^, r^ 5^ e r^ 6^ cada qual é h, halogênio etc. , um sal farmaceuticamente aceitável do derivado, ou um pró-medicamento de qualquer um deles. eles têm excelente atividade inibitória de sglti humano e são úteis como um agente preventivo ou terapêutico para doenças atribuídas à hiperglicemia, tais como diabetes, tolerância à glicose diminuída, anormalidades na ingestão de açúcar no sangue, complicações de diabetes e obesidade, e para doenças atribuídas a um maior nível de galactose no sangue, tal como galactosemia.
BRPI0313694A 2002-08-23 2003-08-21 derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção BRPI0313694B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002244381 2002-08-23
JP2002-244381 2002-08-23
JP2002324076A JP2004137245A (ja) 2002-08-23 2002-11-07 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2002-324076 2002-11-07
PCT/JP2003/010551 WO2004018491A1 (ja) 2002-08-23 2003-08-21 ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体

Publications (3)

Publication Number Publication Date
BR0313694A BR0313694A (pt) 2005-07-05
BRPI0313694B1 BRPI0313694B1 (pt) 2017-12-19
BRPI0313694B8 true BRPI0313694B8 (pt) 2021-05-25

Family

ID=31949579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313694A BRPI0313694B8 (pt) 2002-08-23 2003-08-21 derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção

Country Status (16)

Country Link
US (2) US7635684B2 (pt)
EP (1) EP1548024B1 (pt)
JP (2) JP2004137245A (pt)
KR (1) KR100985504B1 (pt)
AU (1) AU2003262263B8 (pt)
BR (1) BRPI0313694B8 (pt)
CA (1) CA2496329C (pt)
ES (1) ES2386140T3 (pt)
IL (1) IL167038A (pt)
MX (1) MXPA05002129A (pt)
NO (1) NO330569B1 (pt)
NZ (1) NZ538423A (pt)
PL (1) PL213094B1 (pt)
RU (1) RU2369613C2 (pt)
TW (1) TW200410980A (pt)
WO (1) WO2004018491A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213095B1 (pl) * 2002-08-08 2013-01-31 Kissei Pharmaceutical Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP4606876B2 (ja) * 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
KR20050089156A (ko) * 2002-12-04 2005-09-07 깃세이 야쿠힌 고교 가부시키가이샤 고혈당증에 기인하는 질환의 예방 또는 치료제
AU2003289440A1 (en) * 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
US7375090B2 (en) * 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
DE102004028241B4 (de) * 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
EP1813611B1 (en) 2004-11-18 2014-10-01 Kissei Pharmaceutical Co., Ltd. 1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same
JP2008007405A (ja) * 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4888840B2 (ja) * 2005-07-22 2012-02-29 味の素株式会社 ピラゾール−ｏ−グリコシド誘導体の調製方法及び前記方法の新規中間体
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
JP2009167103A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd ピラゾリル５−チオグリコシド化合物
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
TW200812995A (en) 2006-05-19 2008-03-16 Taisho Pharmaceutical Co Ltd C-phenyl glycitol compound
RU2434862C2 (ru) 2006-06-29 2011-11-27 Тайсо Фармасьютикал Ко., Лтд. С-фенил-1-тиоглюцитолы
AU2007332476A1 (en) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
EP2228378B1 (en) 2007-12-27 2015-09-09 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
EP2275430B1 (en) * 2008-04-16 2012-05-16 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
SG173801A1 (en) 2009-02-23 2011-09-29 Taisho Pharmaceutical Co Ltd 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
TW201105336A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Combined medicine of pyrazole derivative and biguanide drug
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
JPWO2011002012A1 (ja) * 2009-07-01 2012-12-13 キッセイ薬品工業株式会社 Ｓｇｌｔ１阻害薬とインスリン抵抗性改善薬を組み合わせてなる医薬
CA2769392A1 (en) 2009-07-31 2011-02-03 Sandoz Ag Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
EP2298782A1 (en) * 2009-08-26 2011-03-23 Sanofi-Aventis Method for producing pyrazole glycoside derivatives
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 ｓｇｌｔ-1/ｓｇｌｔ-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
WO2011048148A2 (en) 2009-10-20 2011-04-28 Novartis Ag Glycoside derivative and uses thereof
EA021983B1 (ru) 2009-11-02 2015-10-30 Пфайзер Инк. Производные диоксабицикло[3.2.1]октан-2,3,4-триола
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012010651A2 (en) 2010-07-23 2012-01-26 Sandoz Ag Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method
EP2607360B1 (en) 2010-08-20 2015-08-19 Taisho Pharmaceutical Co., Ltd. 4-Isopropyl-6-methoxyphenyl glucitol compound
US8822674B2 (en) 2010-08-20 2014-09-02 Taisho Pharmaceutical Co., Ltd Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
KR20140019834A (ko) 2011-04-14 2014-02-17 노파르티스 아게 글리코시드 유도체 및 그의 용도
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
CA2872002C (en) 2012-05-07 2019-01-15 Masayuki Isaji Pyrazole derivative and use thereof for medical purposes
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) * 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
PL3489226T3 (pl) 2012-11-20 2021-08-02 Lexicon Pharmaceuticals, Inc. Inhibitory kotransportera glukozowo-sodowego 1
EP2952206B1 (en) 2013-02-04 2018-10-24 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
WO2019149178A1 (zh) 2018-01-31 2019-08-08 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其用途
CA3094118A1 (en) * 2018-03-28 2019-10-03 Avolynt Method for treating post-prandial hypoglycemia
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112021024165A2 (pt) * 2019-05-31 2022-04-26 Avolynt Composições e métodos para o tratamento de doenças metabólicas
WO2024254354A1 (en) * 2023-06-06 2024-12-12 Vogenx Compositions and methods for treating refractory or intractable epilepsy
EP4724074A1 (en) * 2023-06-06 2026-04-15 Vogenx Compositions and methods for treating hyperinsulinemic hypoglycemia
WO2025117962A1 (en) * 2023-12-01 2025-06-05 Vogenx Compositions and methods for treating glucose-dependent insulinotropic peptide-dependent cushing's syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351898A1 (en) * 1999-04-06 2003-06-30 Sankyo Co O-substituted derivatives of carboxylic acids
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE455785T1 (de) * 2000-11-02 2010-02-15 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
PL209375B1 (pl) 2000-12-28 2011-08-31 Kissei Pharmaceutical Pochodne glukopiranozyloksypirazolu, kompozycja farmaceutyczna zawierająca takie pochodne i zastosowanie tych pochodnych do wytwarzania kompozycji farmaceutycznej
PL213095B1 (pl) * 2002-08-08 2013-01-31 Kissei Pharmaceutical Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CA2500873C (en) * 2002-10-04 2012-01-17 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
EP1637539B1 (en) * 2003-06-20 2012-01-18 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, drug composition containing the same and production intermediate therefor

Also Published As

Publication number Publication date
HK1082744A1 (zh) 2006-06-16
US20050272669A1 (en) 2005-12-08
NO20051411L (no) 2005-04-26
RU2369613C2 (ru) 2009-10-10
US8324176B2 (en) 2012-12-04
AU2003262263B8 (en) 2009-08-06
KR20050038633A (ko) 2005-04-27
JP4597048B2 (ja) 2010-12-15
WO2004018491A1 (ja) 2004-03-04
EP1548024A4 (en) 2010-05-12
MXPA05002129A (es) 2005-06-03
BRPI0313694B1 (pt) 2017-12-19
CA2496329A1 (en) 2004-03-04
PL213094B1 (pl) 2013-01-31
AU2003262263A1 (en) 2004-03-11
JP2004137245A (ja) 2004-05-13
JPWO2004018491A1 (ja) 2005-12-08
KR100985504B1 (ko) 2010-10-05
TW200410980A (en) 2004-07-01
IL167038A (en) 2010-11-30
US20090203633A1 (en) 2009-08-13
CA2496329C (en) 2012-05-15
RU2005108055A (ru) 2006-02-10
BR0313694A (pt) 2005-07-05
EP1548024B1 (en) 2012-06-06
PL375551A1 (en) 2005-11-28
TWI298071B (pt) 2008-06-21
AU2003262263B2 (en) 2009-06-25
US7635684B2 (en) 2009-12-22
EP1548024A1 (en) 2005-06-29
NZ538423A (en) 2007-02-23
NO330569B1 (no) 2011-05-16
ES2386140T3 (es) 2012-08-10

Similar Documents

Publication Publication Date Title
BRPI0313694B8 (pt) derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
BR0013667A (pt) Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos
EP1803721A4 (en) NEW GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT AND THERAPEUTIC AGENT AGAINST DIABETES CONTAINING THIS
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
CY1112772T1 (el) Μεθοδος για την τροποποιηση κρυσταλλικου σχηματισμου φαρμακου του αλατος μυκοφαινολικου νατριου
DE50102490D1 (de) Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
BRPI0513752A (pt) derivado de ciclohexano, pró-droga do mesmo e sal do mesmo e agente terapêutico contendo o mesmo para diabetes
BR0313461A (pt) Novas imidazopiridinas e respectivo uso das mesmas
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
NO20081369L (no) Fenyl- og pyridinyl-1,2,4-oksadiazolonderivater, fremgangsmate for deres fremstilling og deres anvendelse som farmasoytika
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
BR0014179A (pt) Modernos derivados de ácido aminodicarboxìlico com propriedades farmacêuticas
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
SE0202429D0 (sv) Novel Compounds
NO20054382L (no) Diarylsykloalkylderivater, deres fremstilling og deres anvendelse som legemiddel
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
NO20044571L (no) Isokinolinderivater
RU2210573C2 (ru) Углеводные производные
BR0208027A (pt) Composto de n-fenilarilsulfonamida, droga contendo o composto como ingrediente ativo, intermediário para o composto, e processos para a produção do mesmo
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BR0111933A (pt) Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
TW200634001A (en) Novel compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/10 (1974.07), A61K 31/7056 (2000.01), A61K

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2788 DE 11/06/2024 POR TER SIDO INDEVIDA.